Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Reactive oxygen species (ROS) generation pathways represent a complex network of biochemical processes responsible for the production of highly reactive oxygen-containing molecules, including superoxide anions, hydrogen peroxide, and hydroxyl radicals. These species are primarily generated as byproducts of the mitochondrial electron transport chain or through the targeted action of enzymes such as NADPH oxidases (NOX), xanthine oxidase, and myeloperoxidase (Sies et al., 2017, Nature Reviews Molecular Cell Biology). Under physiological conditions, ROS function as critical secondary messengers in signal transduction, regulating processes like cell growth, differentiation, and the immune response (Finkel, 2011, Nature). However, an imbalance between ROS production and the cell's antioxidant defense mechanisms leads to oxidative stress, which causes cumulative damage to DNA, lipids, and proteins. This oxidative damage is a central driver in the pathogenesis of various chronic conditions, including atherosclerosis, Parkinson's disease, and various cancers (Schieber & Chandel, 2014, Current Biology). Pharmacological targeting of ROS generation pathways aims to restore redox homeostasis by either inhibiting the enzymatic sources of ROS or utilizing antioxidant compounds to neutralize excess radicals. For example, xanthine oxidase inhibitors like allopurinol are used clinically to treat gout by reducing ROS and uric acid production, while NOX inhibitors are being investigated for fibrotic and inflammatory diseases (Lambeth & Neish, 2014, Annual Review of Pathology). Despite their therapeutic potential, targeting these pathways is challenging due to the dual role of ROS in both health and disease, necessitating high specificity to avoid disrupting essential physiological signaling.
Therapeutic intervention involves the inhibition of specific ROS-generating enzymes such as NADPH oxidase (NOX) or xanthine oxidase, the decoupling of mitochondrial electron transport, or the direct scavenging of reactive intermediates to prevent oxidative damage and modulate redox-sensitive signaling cascades.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reactive oxygen species generation pathways (ROS generation pathways).